Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Multiple Myeloma Specialty Channel

Multiple Myeloma
Specialty Channel
News
10/10/2024
Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...
Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...
Nivolumab plus pomalidomide and...
10/10/2024
Oncology
News
09/26/2024
Patients with triple class exposed/refractory multiple myeloma treated with belantamab mafodotin plus pomalidomide-dexamethasone achieved high clinical response rates with durable remissions, determined a post-hoc analysis of the ALGONQUIN...
Patients with triple class exposed/refractory multiple myeloma treated with belantamab mafodotin plus pomalidomide-dexamethasone achieved high clinical response rates with durable remissions, determined a post-hoc analysis of the ALGONQUIN...
Patients with triple class...
09/26/2024
Oncology
FDA Approval
09/20/2024
The US Food and Drug Administration granted approval to isatuximab with bortezomib, lenalidomide, and dexamethasone for the frontline treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplant.
The US Food and Drug Administration granted approval to isatuximab with bortezomib, lenalidomide, and dexamethasone for the frontline treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplant.
The US Food and Drug...
09/20/2024
Oncology
News
07/09/2024
Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.
Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.
Phase 2 results from the SELECT...
07/09/2024
Oncology
News
05/20/2024

Amber Denham

Amber Denham
According to results from a multi-institutional real-world study, teclistamab yielded rapid achievement of deep hematologic response among heavily pre-treated patients with relapsed/refractory multiple myeloma.
According to results from a multi-institutional real-world study, teclistamab yielded rapid achievement of deep hematologic response among heavily pre-treated patients with relapsed/refractory multiple myeloma.
According to results from a...
05/20/2024
Oncology
News
04/19/2024

Jordan Kadish 

Jordan Kadish 
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an...
04/19/2024
Oncology
News
04/09/2024

Amber Denham

Amber Denham
According to phase 3 data from the KarMMa-3 trial, the CAR T-cell therapy idecabtagene vicleucel demonstrates improved health-related quality of life compared with standard regimens among patients with relapsed/refractory multiple myeloma...
According to phase 3 data from the KarMMa-3 trial, the CAR T-cell therapy idecabtagene vicleucel demonstrates improved health-related quality of life compared with standard regimens among patients with relapsed/refractory multiple myeloma...
According to phase 3 data from...
04/09/2024
Oncology
News
04/02/2024

Jordan Kadish

Jordan Kadish
Real-world triple-class exposed patients with relapsed/refractory multiple myeloma who received a subsequent line of treatment exhibited poor outcomes, according to a retrospective observational cohort study.
Real-world triple-class exposed patients with relapsed/refractory multiple myeloma who received a subsequent line of treatment exhibited poor outcomes, according to a retrospective observational cohort study.
Real-world triple-class exposed...
04/02/2024
Oncology
News
04/01/2024

Amber Denham

Amber Denham
According to a long-term updated analysis, 3 years of bortezomib, lenalidomide, and dexamethasone maintenance did not improve outcomes for patients with high-risk multiple myeloma defined by gene expression profiling.
According to a long-term updated analysis, 3 years of bortezomib, lenalidomide, and dexamethasone maintenance did not improve outcomes for patients with high-risk multiple myeloma defined by gene expression profiling.
According to a long-term updated...
04/01/2024
Oncology
News
03/18/2024

Amber Denham

Amber Denham
The novel myeloma CAR T Relapse prognostic model may be useful in strategizing optimal timing of CAR T-cell therapy in certain subgroups of patients with R/R MM, according to an international, retrospective study.
The novel myeloma CAR T Relapse prognostic model may be useful in strategizing optimal timing of CAR T-cell therapy in certain subgroups of patients with R/R MM, according to an international, retrospective study.
The novel myeloma CAR T Relapse...
03/18/2024
Oncology

Advertisement

News

News
07/09/2024
Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.
Phase 2 results from the SELECT study demonstrated that weekly carfilzomib, pomalidomide, and dexamethasone treatment showed efficacy and tolerability among patients with relapsed/refractory multiple myeloma.
Phase 2 results from the SELECT...
07/09/2024
Oncology
News
05/20/2024

Amber Denham

Amber Denham
According to results from a multi-institutional real-world study, teclistamab yielded rapid achievement of deep hematologic response among heavily pre-treated patients with relapsed/refractory multiple myeloma.
According to results from a multi-institutional real-world study, teclistamab yielded rapid achievement of deep hematologic response among heavily pre-treated patients with relapsed/refractory multiple myeloma.
According to results from a...
05/20/2024
Oncology
News
04/19/2024

Jordan Kadish 

Jordan Kadish 
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an...
04/19/2024
Oncology
News
04/09/2024

Amber Denham

Amber Denham
According to phase 3 data from the KarMMa-3 trial, the CAR T-cell therapy idecabtagene vicleucel demonstrates improved health-related quality of life compared with standard regimens among patients with relapsed/refractory multiple myeloma...
According to phase 3 data from the KarMMa-3 trial, the CAR T-cell therapy idecabtagene vicleucel demonstrates improved health-related quality of life compared with standard regimens among patients with relapsed/refractory multiple myeloma...
According to phase 3 data from...
04/09/2024
Oncology
News
04/02/2024

Jordan Kadish

Jordan Kadish
Real-world triple-class exposed patients with relapsed/refractory multiple myeloma who received a subsequent line of treatment exhibited poor outcomes, according to a retrospective observational cohort study.
Real-world triple-class exposed patients with relapsed/refractory multiple myeloma who received a subsequent line of treatment exhibited poor outcomes, according to a retrospective observational cohort study.
Real-world triple-class exposed...
04/02/2024
Oncology
News
04/01/2024

Amber Denham

Amber Denham
According to a long-term updated analysis, 3 years of bortezomib, lenalidomide, and dexamethasone maintenance did not improve outcomes for patients with high-risk multiple myeloma defined by gene expression profiling.
According to a long-term updated analysis, 3 years of bortezomib, lenalidomide, and dexamethasone maintenance did not improve outcomes for patients with high-risk multiple myeloma defined by gene expression profiling.
According to a long-term updated...
04/01/2024
Oncology
News
03/18/2024

Amber Denham

Amber Denham
The novel myeloma CAR T Relapse prognostic model may be useful in strategizing optimal timing of CAR T-cell therapy in certain subgroups of patients with R/R MM, according to an international, retrospective study.
The novel myeloma CAR T Relapse prognostic model may be useful in strategizing optimal timing of CAR T-cell therapy in certain subgroups of patients with R/R MM, according to an international, retrospective study.
The novel myeloma CAR T Relapse...
03/18/2024
Oncology
News
03/05/2024

Jordan Kadish

Jordan Kadish
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial, adding daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy yielded beneficial outcomes among transplantation-eligible patients with newly diagnosed multiple...
According to a phase 3 trial,...
03/05/2024
Oncology
FDA Approval
02/21/2024
On February 20, 2024, the FDA granted approval for teclistamab administered with biweekly dosing for patients with relapsed/refractory multiple myeloma.
On February 20, 2024, the FDA granted approval for teclistamab administered with biweekly dosing for patients with relapsed/refractory multiple myeloma.
On February 20, 2024, the FDA...
02/21/2024
Oncology
News
02/16/2024
The addition of elotuzumab to lenalidomide, bortezomib, and dexamethasone induction or consolidation and lenalidomide maintenance fails to provide clinical benefit for patients with transplant-eligible newly diagnosed multiple myeloma who are...
The addition of elotuzumab to lenalidomide, bortezomib, and dexamethasone induction or consolidation and lenalidomide maintenance fails to provide clinical benefit for patients with transplant-eligible newly diagnosed multiple myeloma who are...
The addition of elotuzumab to...
02/16/2024
Oncology

Interactive Features

Quiz
01/30/2024
According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...
According to an interim analysis from the CARTBCMA-HCB-01 pilot study, ARI0002h, a BCMA-targeted CAR T-cell therapy developed within the academic setting, demonstrated encouraging responses when administered in a fractionated manner with a...
According to an interim analysis...
01/30/2024
Oncology
Quiz
01/19/2024
True or False: The oral combination of mezigdomide plus dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma (MM), according to findings from a phase 1/2 study.
True or False: The oral combination of mezigdomide plus dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory (R/R) multiple myeloma (MM), according to findings from a phase 1/2 study.
True or False: The oral...
01/19/2024
Oncology
Quiz
04/18/2023
In a study assessing the efficacy and safety of ciltacabtagene autoleucel CAR-T-cell therapy among patients with R/R multiple myeloma who had been previously exposed to noncellular anti-B-cell maturation antigen therapies, what was the...
In a study assessing the efficacy and safety of ciltacabtagene autoleucel CAR-T-cell therapy among patients with R/R multiple myeloma who had been previously exposed to noncellular anti-B-cell maturation antigen therapies, what was the...
In a study assessing the...
04/18/2023
Oncology
Quiz
09/13/2022
True or False: Among adults with multiple myeloma, triplet therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus autologous stem-cell transplantation was associated with longer progression-free survival than RVD alone, according...
True or False: Among adults with multiple myeloma, triplet therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus autologous stem-cell transplantation was associated with longer progression-free survival than RVD alone, according...
True or False: Among adults with...
09/13/2022
Oncology
Quiz
09/02/2022
True or false: In a phase 2 study, an MRD-adapted study design employing a quadruplet therapy regimen of elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in...
True or false: In a phase 2 study, an MRD-adapted study design employing a quadruplet therapy regimen of elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without transplant was associated with deep, durable responses in...
True or false: In a phase 2...
09/02/2022
Oncology
Quiz
08/24/2022
Quiz: Among patients with triple-class exposed relapsed/refractory MM on a phase 1-2 study, treatment with teclistamab led to an overall response rate of which of the following?
Quiz: Among patients with triple-class exposed relapsed/refractory MM on a phase 1-2 study, treatment with teclistamab led to an overall response rate of which of the following?
Quiz: Among patients with...
08/24/2022
Oncology
Test Your Knowledge
02/01/2022
True or false: TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, is not well tolerated in patients with R/R MM.
True or false: TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, is not well tolerated in patients with R/R MM.
True or false: TNB-383B, a BCMA...
02/01/2022
Oncology
Test Your Knowledge
02/01/2022
True or false: Gamma secretase inhibitors increase BCMA expression on MM cells.
True or false: Gamma secretase inhibitors increase BCMA expression on MM cells.
True or false: Gamma secretase...
02/01/2022
Oncology
Test Your Knowledge
01/27/2022
True or false: Teclistamab targets both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressive myeloma cells.
True or false: Teclistamab targets both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressive myeloma cells.
True or false: Teclistamab...
01/27/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement